Additionally, treatment with setmelanotide resulted in a mean reduction in MetS-Z-BMI scores after 1 year of treatment, indicating that setmelanotide has the potential to reduce the severity of metabolic syndrome, in addition to weight and hunger in patients with BBS (2). Here, BBS2 is linked to metabolic syndrome.